{"id":"W2599986538","doi":"10.1200/jco.2013.31.15_suppl.2523","title":"A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada); Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Afatinib; Internal medicine; Maximum tolerated dose; Gastroenterology; Pharmacology; Urology; Nuclear medicine; Cancer; Erlotinib; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001216063,0.00140537,0.001516726,0.0002986191,0.0003443533,0.0009029038,0.0007616752,0.0009958446,0.004030024],"category_scores_gemma":[0.0008053316,0.0005111941,0.00147371,0.0004051306,0.0008331981,0.0007887633,0.0003914403,0.002833514,0.0009882],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000906828,"about_ca_system_score_gemma":0.001227723,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008934056,"about_ca_topic_score_gemma":0.001846576,"domain_scores_codex":[0.9997094,0.0001177713,0.00001470903,0.00007119257,0.00002238809,0.00006448825],"domain_scores_gemma":[0.9993492,0.0001079156,0.00009885157,0.00005031161,0.00003949071,0.0003542493],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8689512,0.0215981,0.004715616,0.0007039548,0.001640855,0.0003131694,0.0002725558,0.002833882,0.03713061,0.0002523348,0.004793843,0.05679395],"study_design_scores_gemma":[0.7422692,0.2427738,0.008835999,0.00002679076,0.0005585791,0.0003181295,0.0000444795,0.001237373,0.00204518,0.0002577404,0.001604934,0.00002772509],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923702,0.001406696,0.0005979686,0.0004082336,0.00008151578,0.00192266,0.00152444,0.00007490216,0.001613368],"genre_scores_gemma":[0.9904048,0.0009135441,0.001566187,0.0005985087,0.00009213169,0.001953044,0.002382401,0.00003096508,0.002058491],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004030024,"threshold_uncertainty_score":0.01348174,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04642476607821685,"score_gpt":0.4568040036674099,"score_spread":0.410379237589193,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}